2024
Real-World Survival, Healthcare Resource Utilization, and Costs Among U.S. Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL) Treated With R-GemOx in the Relapsed/Refractory Setting
Garg M, Puckett J, Kamal-Bahl S, Raut M, Ryland K, Doshi J, Huntington S. Real-World Survival, Healthcare Resource Utilization, and Costs Among U.S. Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL) Treated With R-GemOx in the Relapsed/Refractory Setting. Clinical Lymphoma Myeloma & Leukemia 2024, 24: e181-e190. PMID: 38433043, DOI: 10.1016/j.clml.2024.01.010.Peer-Reviewed Original ResearchDiffuse large B-cell lymphomaHealthcare resource utilizationR-GemOxOverall survivalR/R settingR/R diffuse large B-cell lymphomaElderly patientsLarge B-cell lymphomaDLBCL diagnosisRates of healthcare resource utilizationCombination of rituximabMedian overall survivalR/R DLBCL patientsB-cell lymphomaStem cell transplantationReal-world survivalHealthcare resource useSample of patientsMicro AbstractRelapsed/refractory settingDLBCL patientsThird-lineSecond-lineCell transplantationPost-index
2020
Challenges and Opportunities in the Management of Diffuse Large B‐Cell Lymphoma in Older Patients
Di M, Huntington SF, Olszewski AJ. Challenges and Opportunities in the Management of Diffuse Large B‐Cell Lymphoma in Older Patients. The Oncologist 2020, 26: 120-132. PMID: 33230948, PMCID: PMC7873335, DOI: 10.1002/onco.13610.Peer-Reviewed Original ResearchConceptsDiffuse large B-cell lymphomaLarge B-cell lymphomaChimeric antigen receptor T-cell therapyB-cell lymphomaChemotherapy-free approachProphylactic growth factorsOlder patientsStem cell transplantationT-cell therapyClinical trialsGeriatric vulnerabilitiesRefractory settingGeriatric assessmentCell transplantationPalliative careStandard first-line treatmentGrowth factorEarly palliative careFit older patientsTolerance of treatmentUnfavorable biologic featuresUnnecessary dose reductionsFirst-line settingFirst-line treatmentFavorable toxicity profile
2019
Peripheral Blood Involvement By Flow Cytometry As a Prognostic Factor in Aggressive T Cell Lymphomas Following Autologous Stem Cell Transplantation
Chandhok N, Huntington S, Isufi I, Gowda L, Xu M, Bar N, Seropian S, Foss F. Peripheral Blood Involvement By Flow Cytometry As a Prognostic Factor in Aggressive T Cell Lymphomas Following Autologous Stem Cell Transplantation. Blood 2019, 134: 4055. DOI: 10.1182/blood-2019-128888.Peer-Reviewed Original ResearchAutologous stem cell transplantationAggressive T-cell lymphomaProgression-free survivalT-cell lymphomaTime of diagnosisPeripheral blood involvementBone marrow involvementStem cell transplantationMedian progression-free survivalOverall survivalCell lymphomaBlood involvementFirst remissionMarrow involvementPrognostic factorsCell transplantationFlow cytometryPeripheral bloodWorse outcomesPositive groupNegative groupExtranodal natural killer T-cell lymphomaBone marrowFront autologous stem cell transplantationNatural killer T-cell lymphoma
2018
Trends in utilization and in-hospital outcomes of high dose therapy and autologous stem cell transplantation among patients with AL amyloidosis in the United States.
Giri S, Mehta K, Hoag J, Huntington S, Dhakal B. Trends in utilization and in-hospital outcomes of high dose therapy and autologous stem cell transplantation among patients with AL amyloidosis in the United States. Journal Of Clinical Oncology 2018, 36: e20000-e20000. DOI: 10.1200/jco.2018.36.15_suppl.e20000.Peer-Reviewed Original Research
2017
Long-term survival of older patients with MDS treated with HMA therapy without subsequent stem cell transplantation
Zeidan AM, Stahl M, Hu X, Wang R, Huntington SF, Podoltsev NA, Gore SD, Ma X, Davidoff AJ. Long-term survival of older patients with MDS treated with HMA therapy without subsequent stem cell transplantation. Blood 2017, 131: 818-821. PMID: 29259002, PMCID: PMC6410557, DOI: 10.1182/blood-2017-10-811729.Peer-Reviewed Original ResearchConceptsSubsequent stem cell transplantationStem cell transplantationLong-term survivalHMA therapyOlder patientsCell transplantationPatientsTransplantationTherapy
2016
Cost-Effectiveness Analysis of Consolidation with Brentuximab Vendotin Versus Active Surveillance in Individuals with High-Risk Hodgkin Lymphoma Undergoing High Dose Chemotherapy with Stem Cell Rescue
Hui L, von Keudell G, Wang R, Zeidan A, Gore S, Ma X, Davidoff A, Huntington S. Cost-Effectiveness Analysis of Consolidation with Brentuximab Vendotin Versus Active Surveillance in Individuals with High-Risk Hodgkin Lymphoma Undergoing High Dose Chemotherapy with Stem Cell Rescue. Blood 2016, 128: 1188. DOI: 10.1182/blood.v128.22.1188.1188.Peer-Reviewed Original ResearchAutologous stem cell transplantationReconstructed individual patient dataIncremental cost-effectiveness ratioR Hodgkin lymphomaIndividual patient dataHodgkin's lymphomaActive surveillanceOverall survivalHealth care costsHL progressionHL recurrenceHealthcare costsCare costsHigh-risk Hodgkin lymphomaSignificant health care costsDouble-blind trialPatient dataUse of BVFirst-line therapyHigh-dose chemotherapyPrimary refractory diseaseProgression-free survivalStem cell rescueLong-term followStem cell transplantation